Download Image
    
Share
  
Post
BI 764198 for COVID-19
1 study with 129 patients
Hospital Icon Control
Hospital Icon BI 764198 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 BI 764198 studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -117% Mortality -117% RCTs -117% Late -117% FavorsBI 764198 Favorscontrol
BI 764198 is an oral, small molecule inhibitor of the transient receptor potential channel 6 (TRPC6), investigated for the potential to reduce COVID-19-related lung injury and progression to ARDS. Recent:
Ware.
Apr 6
2023
 Ware et al., Thorax, doi:10.1136/thorax-2022-219668 TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial
117% higher mortality (p=0.18), 12% higher progression (p=0.84), and 42% worse recovery (p=0.48). RCT 129 hospitalized COVID-19 patients requiring non-invasive oxygen support showing no benefit and potential harm with BI 764198 (TRPC6 inhibitor). The study was terminated early due to lack of efficacy and an imbalance of fatal events (..